Imagen offers oncology pharmacology services utilizing the world’s largest biobank of patient derived cell (PDC) models of cancer.

Utilizing our global clinical network to source an array of primary and refractory tumor material and our proprietary culture methods we can develop low passage, clinically relevant models. Studies can be run from the >500 models in our biobank, or we can custom build cohorts of models from specific patient selection criteria.

Each model comes with the patient treatment history and NGS (WES, RNASeq), as well as in vitro response to 60+ anticancer chemotherapeutics.

With these PDCs and their corresponding data, we offer a unique opportunity to screen investigational drugs using a wide range of endpoints

Our PDC platform supports companies across the drug development pipeline from pre-clinical to translational screening and clinical patient profiling.